MedTrace Logo

Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder

NCT05271084 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-09-07

No results posted yet for this study

Summary

The aim of this study is to test if combining the antidepressant Citalopram with Pentoxifylline (PTX), a medicine with anti-inflammatory and phosphodiesterase inhibitory properties, enhanced antidepressant efficacy in adult patients with major depressive disorder (MDD) when compared to Citalopram alone.

Conditions

Interventions

DRUG

Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg

Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties

DRUG

Citalopram (tablet) 20 mg + Placebo (tablet)

Selective serotonin reuptake inhibitor (SSRI) + placebo

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Talar A Merzamohammad, Pharm. D · Hawler Medical University, College of Pharmacy, Department of Pharmacology and Toxicology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-10
Primary Completion
2022-02-25
Completion
2022-06-08

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05271084 on ClinicalTrials.gov